On the Origins of the Androgen Receptor Low Molecular Weight Species

Hormones and Cancer

Volumn 4, Issue 5, 2013, Pages 259-269

  Mudryj, Maria ^a,b   Tepper, Clifford G ^c  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b Department of Medical Microbiology and Immunology ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CALPAIN; ESTRADIOL; ESTROGEN; GLUCOCORTICOID; LOW MOLECULAR WEIGHT ANDROGEN RECEPTOR; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANDROGEN INSENSITIVITY SYNDROME; BINDING SITE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL SURVIVAL; DNA BINDING; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; LIGAND BINDING; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ANDROGENS; HUMANS; MALE; MOLECULAR WEIGHT; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84884164606     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0152-z     Document Type: Review

References (74)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Taplin ME, Balk SP (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483-490.
3. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5: 1396-1404.
4. Javidan J, Deitch AD, Shi XB, de Vere White RW (2005) The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest 23: 520-528.
5. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH (1991) Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 39: 927-936.
6. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147: 798-803.
7. Sadi MV, Walsh PC, Barrack ER (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67: 3057-3064.
8. Devlin HL, Mudryj M (2009) Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186.
9. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS (1998) Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58: 5718-5724.
10. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614.
11. Pretlow TG et al (1993) Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 85: 394-398.
12. Wainstein MA et al (1994) CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 54: 6049-6052.
13. Nagabhushan M et al (1996) CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56: 3042-3046.
14. Tan J et al (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11: 450-459.
15. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM (2011) Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71: 2108-2117.
16. Wellington CL et al (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158-9167.
17. Sheflin L, Keegan B, Zhang W, Spaulding SW (2000) Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276: 144-150.
18. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M (2007) Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67: 9001-9005.
19. Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83: 731-801.
20. Murayama A, Fukai F, Murachi T (1984) Action of calpain on the basic estrogen receptor molecule of porcine uterus. J Biochem 95: 1697-1704.
21. Kim YS, Kim J, Kim Y, Lee YH, Kim JH, Lee SJ, Shin SY, Ko J (2008) The role of calpains in ligand-induced degradation of the glucocorticoid receptor. Biochem Biophys Res Commun 374: 373-377.
22. Pelley RP, Chinnakannu K, Murthy S, Strickland FM, Menon M, Dou QP, Barrack ER, Reddy GP (2006) Calmodulin-androgen receptor (AR) interaction: calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells. Cancer Res 66: 11754-11762.
23. Tompa P, Buzder-Lantos P, Tantos A, Farkas A, Szilagyi A, Banoczi Z, Hudecz F, Friedrich P (2004) On the sequential determinants of calpain cleavage. J Biol Chem 279: 20775-20785.
24. Chen H, Libertini SJ, Wang Y, Kung HJ, Ghosh P, Mudryj M (2010) ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem 285: 2368-2374.
25. Glading A, Chang P, Lauffenburger DA, Wells A (2000) Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem 275: 2390-2398.
26. Frezza M, Yang H, Dou QP (2011) Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli. J Cell Physiol 226: 2731-2739.
27. Harada N, Inoue K, Yamaji R, Nakano Y, Inui H (2012) Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells. Cancer Sci 103: 1022-1027.
28. Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, Rubin MA, Day ML (2003) The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 278: 1372-1379.
29. Ceraline J et al (2004) Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108: 152-157.
30. Lapouge G et al (2007) Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-a new paradigm for cooperation among prostate tumor cells. Int J Cancer 121: 1238-1244.
31. Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, Bergerat JP, Ceraline J (2008) Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 617: 529-534.
32. Streicher W et al (2012) AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J Urol 30: 333-339.
33. Zengerling F, Streicher W, Schrader AJ, Schrader M, Nitzsche B, Cronauer MV, Hopfner M (2012) Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. Int J Mol Sci 13: 11530-11542.
34. Quigley CA et al (1992) Complete androgen insensitivity due to deletion of exon C of the androgen receptor gene highlights the functional importance of the second zinc finger of the androgen receptor in vivo. Mol Endocrinol 6: 1103-1112.
35. Zhu X, Daffada AA, Chan CM, Dowsett M (1997) Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer 72: 574-580.
36. Jagla M, Feve M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat JP, Ceraline J (2007) A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 148: 4334-4343.
37. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
38. Guo Z et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
39. Hu R et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
40. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71: 1656-1667.
41. Yang X et al (2011) Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem 286: 36152-36160.
42. Marcias G et al (2010) Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 31: 74-80.
43. Sun S et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
44. Hu R et al (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72: 3457-3462.
45. Zhao H, Coram MA, Nolley R, Reese SW, Young SR, Peehl DM (2012) Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. J Urol 188: 2158-2164.
46. Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287: 19736-19749.
47. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73: 483-489.
48. Mediwala SN et al (2013) The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate 73: 267-277.
49. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6: e19059.
50. Zhang X et al (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6: e27970.
51. Tsai HC, Boucher DL, Martinez A, Tepper CG, Kung HJ (2012) Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target. PLoS One 7: e49887.
52. Chen H et al (2010) Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer 17: 857-873.
53. Shafi AA, Cox MB, Weigel NL (2013) Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78(6): 548-554. doi: 10. 1016/j. steroids. 2012. 12. 013.
54. Peacock SO, Fahrenholtz CD, Burnstein KL (2012) Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol 26: 1967-1979.
55. Li Y et al (2012) AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31: 4759-4767.
56. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107: 16759-16765.
57. Cammas A, Lewis SM, Vagner S, Holcik M (2008) Post-transcriptional control of gene expression through subcellular relocalization of mRNA binding proteins. Biochem Pharmacol 76: 1395-1403.
58. David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24: 2343-2364.
59. Shiota M, Yokomizo A, Naito S (2012) Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocr Relat Cancer 19: R243-R253.
60. Dutertre M, Sanchez G, Barbier J, Corcos L, Auboeuf D (2011) The emerging role of pre-messenger RNA splicing in stress responses: sending alternative messages and silent messengers. RNA Biol 8: 740-747.
61. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G (2006) Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 66: 9502-9508.
62. Singh RK, Tapia-Santos A, Bebee TW, Chandler DS (2009) Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress. Exp Cell Res 315: 3419-3432.
63. Higashide S et al (2004) Identification of regulatory cis-acting elements for alternative splicing of presenilin 2 exon 5 under hypoxic stress conditions. J Neurochem 91: 1191-1198.
64. Amir-Ahmady B, Salati LM (2001) Regulation of the processing of glucose-6-phosphate dehydrogenase mRNA by nutritional status. J Biol Chem 276: 10514-10523.
65. van der Houven van Oordt W, Diaz-Meco MT, Lozano J, Krainer AR, Moscat J, Caceres JF (2000) The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J Cell Biol 149: 307-316.
66. Shomron N, Alberstein M, Reznik M, Ast G (2005) Stress alters the subcellular distribution of hSlu7 and thus modulates alternative splicing. J Cell Sci 118: 1151-1159.
67. Cohen AA et al (2008) Dynamic proteomics of individual cancer cells in response to a drug. Science 322: 1511-1516.
68. Busa R, Geremia R, Sette C (2010) Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin. Nucleic Acids Res 38: 3005-3018.
69. Paronetto MP et al (2010) Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res 70: 229-239.
70. Comstock CE et al (2009) Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 15: 5338-5349.
71. Andersen RJ et al (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17: 535-546.
72. Nakka M, Agoulnik IU, Weigel NL (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45: 763-772.
73. Yamashita S et al (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14: 74-83.
74. Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X (2012) Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One 7: e31213.